Back


17/01/2019
Asceneuron appoints Peter Van Vlasselaer as Chairman
Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as Chair of the Board of Directors. [...]

Download the pdf file





X

X